Semaglutide Off-Patent in India: Access Challenges Ahead
As semaglutide transitions off-patent in India, the existing access rules may not align with the diverse cardiovascular risk profiles of potential users.
The off-patent status of semaglutide in India raises significant questions regarding access for patients. Current regulations were established with specific cardiovascular risk profiles in mind, potentially excluding those who may benefit from the medication.
The implications of these rules are critical for healthcare infrastructure, as they may limit the distribution of semaglutide to a narrow segment of the population. This could lead to disparities in treatment access, particularly among those with varying health conditions.
A reevaluation of access criteria is necessary to ensure that semaglutide reaches all individuals who require it, regardless of their cardiovascular risk. This will require collaboration between healthcare providers and policymakers to adapt existing frameworks.